News	Events
Publications	Companies
Clinical Trials

Tag Archives: TTR

• Alnylam Reports Positive ALN-TTR02 Clinical Data, with Robust Knockdown of Serum Transthyretin (TTR) of up to 94% After Single Dose

  0 Replies
  

  July 16, 2012

  – Results of Clinical Study Demonstrate Rapid, Dose-Dependent, Durable, and Specific Knockdown of TTR, the Disease-Causing Protein in TTR-Mediated Amyloidosis (ATTR) – – Company to Host Conference Call Today, July 16 at 8:30 a.m. ET to Discuss Results – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 16, 2012-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a... Contine Reading & Discuss→

• Alnylam Completes Enrollment in Phase I Clinical Trial and Initiates Phase II Clinical Trial of ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)

  0 Replies
  

  June 07, 2012

  – Company to Present Data from Phase I Study Early in Third Quarter – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 7, 2012-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has completed enrollment in its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR)... Contine Reading & Discuss→

• Alnylam Initiates Phase I Clinical Study of ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)

  0 Replies
  

  March 19, 2012

  – Data Demonstrating TTR Knockdown Expected in Third Quarter of 2012 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 19, 2012-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene... Contine Reading & Discuss→